aldoxorubicin aldoxorubicin aldoxorubicin (inno-206) is a tumor-targeted doxorubicin conjugate in development by cytrx. specifically, it is the (6-maleimidocaproyl) hydrazone of doxorubicin. essentially, this chemical name describes doxorubicin attached to an acid-sensitive linker (n-ε-maleimidocaproic acid hydrazide, or emch). aldoxorubicinidentifiers iupac name n-oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide cas number1361644-26-9pubchem cid71300693chemspider7986464uniic28mv4im0bkeggd10383echa infocard100.244.879 chemical and physical dataformulac37h42n4o13molar mass750.758 g·mol−13d model (jsmol)interactive image smiles c1((c(o1)o2c(cc3=c(c4=c(c(=c23)o)c(=o)c5=c(c4=o)c=cc=c5oc)o)(c(=nnc(=o)cccccn6c(=o)c=cc6=o)co)o)n)o inchi inchi=1s/c37h42n4o13/c1-17-32(46)20(38)13-27(53-17)54-22-15-37(51,23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49/h6-8,10-11,17,20,22,27,32,42,46,48,50-51h,3-5,9,12-16,38h2,1-2h3,(h,40,43)/t17-,20-,22-,27-,32+,37-/m0/s1key:obmjqrliqqtjlr-frtgxrtisa-n the proposed mechanism of action is as follows: after administration, aldoxorubicin rapidly binds endogenous circulating albumin through the emch linker. circulating albumin preferentially accumulates in tumors, bypassing uptake by other non-specific sites including heart, bone marrow and gastrointestinal tract. once albumin-bound aldoxorubicin reaches the tumor, the acidic environment of the tumor causes cleavage of the acid sensitive linker. free doxorubicin is released at the site of the tumor. clinical trials five phase i trials for safety characterization have been completed. several phase ii and iii trials are underway. phase ii as of january 2017, there are 6 phase ii clinical trials in progress: second-line therapy for patients with glioblastoma treatment of hiv-positive patients with kaposi's sarcoma combination therapy of ifosfamide and aldoxorubicin for treatment of metastatic or locally advanced sarcoma comparison of aldoxorubicin to the gold-standard treatment, topotecan, for metastatic small cell lung cancer treatment of advanced or metastatic pancreatic ductal adenocarcinoma comparison of aldoxorubicin and doxorubicin for patients with metastatic or locally advanced carcinoma phase iii a phase iii trial for patients with relapsed soft tissue sarcoma comparing aldoxorubicin with several other chemotherapeutics is expected to complete in 2018. in november 2016, cytrx announced that preliminary results had been positive.